A new class of NO-donor pro-drugs triggered by γ-glutamyl transpeptidase with potential for reno-selective vasodilatation by Zhang, Qingzhi et al.
This journal is c The Royal Society of Chemistry 2013 Chem. Commun., 2013, 49, 1389--1391 1389
Cite this: Chem. Commun.,2013,
49, 1389
A new class of NO-donor pro-drugs triggered by
c-glutamyl transpeptidase with potential for
reno-selective vasodilatation†
Qingzhi Zhang,*a Agnieszka Kulczynska,a David J. Webb,b Ian L. Megson*c and
Nigel P. Bottingz*a
This communication describes the synthesis of a new class of
N-hydroxyguanidine (NHG) pro-drugs which release nitric oxide
(NO), triggered by the action of c-glutamyl transpeptidase (c-GT),
and have potential for the treatment of acute renal injury/failure
(ARI/ARF).
Acute renal injury (AKI), or failure (ARF), is a common compli-
cation that aﬀects millions of people worldwide, particularly in
intensive care units, where it is associated with a mortality rate
of between 50% and 80%.1 There is no eﬀective pharmaceutical
therapy to date. One of the major causes of AKI is ischemia-
reperfusion injury,2,3 following aortic ring cross-clamping
during by-pass surgery, which can lead to renal ischemia.4
Reperfusion of ischemic renal tissue causes the generation of
reactive oxygen species which induce renal cell injury5 and
promote impairment of renal perfusion at least in part via
inactivation of the vasodilator, nitric oxide (NO).6–8 Thus, a
kidney selective vasodilator with antioxidant properties is
attractive to maintain blood flow to oﬀset AKI and scavenge
the reactive oxygen species. Localisation of activity to the
kidney would avoid a systemic reduction in blood pressure.
Dopamine and fenoldopam, specific agonists of the dopamine-
1 receptor, have been used clinically in an eﬀort to reduce the
risk of perioperative renal dysfunction, but the eﬀectiveness
of these agents is not clear.9,10 We hypothesised that an
eﬀective exogenous NO-donor, which selectively increases renal
vasodilatation, would oﬀer an alternative.
There are a wide range of NO-donor drugs in existence,11
including conventional organic nitrates and nitrites, S-nitrothiols,
NONOates and N-hydroxyguanidines (NHGs).12–16 The NHGs
1 are analogues of No-hydroxy-L-arginine (NOHA), a biosyn-
thetic intermediate involved in the generation of NO from
L-arginine.11 Several enzymatically activated NHG pro-drugs
have been reported such as peptidylglycine a-amidating mono-
oxygenase (PAM)-active O-carboxymethyl N-hydroxyguanidines17
and N-b-galactosidases-active (b-D-galactopyranos-1-yl)oxyguani-
dine.18 Our approach aimed to mask the NO generating N-OH
group with a g-glutamyl residue to facilitate activation by the
enzyme, g-glutamyl transpeptidase (g-GT). Given that g-GT is
primarily expressed in the kidney (5–10 fold higher than in the
liver and pancreas),19 it was envisaged that this enzyme could be
used to trigger reno-selective release of an NHG and subsequent
in situ generation of NO (Scheme 1). A similar strategy has
been described for reno-selective L-3,4-dihydroxyphenylalanine
(L-DOPA), the Glu-DOPA.20,21
However, the direct coupling of NHGs with a g-glutamyl
residue was hampered by intramolecular cyclization and
dehydration leading to a 1,2,4-oxadiazole ring; or alternatively
lactamization and release of a pyroglutamic acid (Scheme 2,
data not included).
In an eﬀort to prevent these modes of cyclization, we
investigated the use of a bridge between the NHG and the
g-glutamyl group. Both g-glutamyl itself and g-aminobutanoyl
(GABA)22 were explored as linkers. Thus 2a and 2b became
synthesis targets (Scheme 3) and they were prepared via
appropriately protected dipeptide intermediates (ESI;† Scheme
S1). Unfortunately 2a gradually decomposed presumably due
to the carboxylic acid moieties promoting autodegradation.
Scheme 1 Approach to g-GT triggered release of NHG 1 and the reno-selective
release of nitric oxide.
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On the other hand, 2b could be purified by preparative HPLC
but was found to be resistant to g-GT-mediated cleavage in vitro
and was considered not to be a useful pro-drug. This prompted
the preparation of 3 (Scheme 3), involving the conjugation of
only one GABA-Glu dipeptide onto a hydroxamic acid, an
alternative NO-donor.11 Compound 3 too, unfortunately, was
found to be resistant to g-GT mediated deacylation, suggesting
that the GABA-Glu peptide linker is not suitable for g-GT
cleavage in this setting.
g-Glutamyl anilines are known substrates for g-GT23 and
presented an alternative linker option. The success of such an
approach would involve a 1,6-elimination following the action
of g-GT on N-g-glutamylaminobenzyloxy-guanidine 4a–c, as
illustrated in Scheme 4. Similar spacers have been employed
previously in anticancer pro-drug design.24
In the event, the synthesis of 4a–c was successfully accom-
plished through a six-step reaction sequence (Scheme 4).
Firstly, g-glutamylation of 4-aminobenzylalcohol with Alloc-
L-glutamic acid 1-allyl ester (Alloc-Glu-OAll) (ESI;† Scheme S1)
gave benzyl alcohol 5. Conversion of the benzylalcohol moiety
to the corresponding bromide 6 followed by nucleophilic dis-
placement with BocNHOH generated aminooxide 7, and then
treatment with CF3COOH–DCM, gave the key intermediate 8
which was coupled with the required amino(alkyl/aryliminio)-
methanesulfonate 9a–c to generate 10a–c. Finally the All/Alloc
groups were removed under neutral conditions with
([Pd(PPh3)4]/PhSiH3) to give 4a–c.
The same aminobenzyl linker was also used for the
g-glutamylation of N-hydroxyformamidines (NHFs) (Scheme 5).
N0-Hydroxy-N-(4-butyl-2-methylphenyl)formamidine25 and N0-hydroxy-
N-(3-chloro-4-morpholin-4-ylphenyl)formamide26 have been docu-
mented as 20-hydroxyeicosatetraenoic acid (20-HETE) inhibitors.
20-HETE is a major metabolite of arachidonic acid and is a potent
vasoconstrictor; localisation of an NHF would counter the eﬀect of
20-HETE and induce a synergic vasodilation eﬀect mediated by
NO. Thus N0-hydroxyphenylethylformamidine 12 was prepared in
this study and converted to pro-drug 14.
Pro-drugs 4a–c and 14 were rapidly cleaved by g-GT and they
were completely deacylated after 1 h, as judged by LC-MS. Fig. 1(a)
and (b) illustrates the LCMS trace of 4b and the conversion of 4b to
deacylated intermediate 15 [M-Glu]+ by g-GT. This was in clear
contrast to the GABA-linked candidates 2b and 3, which proved to
be resistant to the action of g-GT. 1,6-Elimination and loss of the
linker from 15 to generate the parent NHG 1b is significantly slower
(trace amount of parent 1b was detected by selective ion monitoring
atm/z 180) than the cleavage of the g-glutamylmoiety. In preliminary
experiments with animal tissue, LC-MS analysis revealed B90%
conversion of 4b (100 mM) to 1b in a rat renal homogenate (37 1C;
45 min). In addition, 4b was found to induce substantial vaso-
dilatation in rat isolated perfused kidney preparations (50% of
maximum vasodilatation induced by B40 mM 4b). Details of the
bioactivity of these pro-drugs will be reported elsewhere.
In summary, several candidate NO-donor pro-drugs have
been prepared, designed for activation by g-GT. The pro-drugs
Scheme 2 Cyclization of direct coupling of NHGs with g-glutamyl residue(s).
Scheme 3 Design of Glu/Gaba linked g-glutamyl NO-donor pro-drugs of NHG
and hydroxamic acid.
Scheme 4 Design and synthesis of aminobenzyl linked g-glutamyl NO-donor
pro-drugs of NHG: (i) 4-aminobenzylalcohol, EEDQ, DCM, rt, 12 h, 85%; (ii) PBr3,
THF, 0 1C, 2 h, 87%; (iii) BocNHOH, NaH, THF, 0 1C, 4 h, 83%; (iv) CF3CO2H, DCM,
92%; (v) 9a R = Ph or 9b R = PhCH2CH2 or 9c R = furfuryl, Et3N, DMAP, DCM,
38–53%; (vi) [Pd(PPh3)4], PhSiH3, DCM, 37–89%.
Scheme 5 Synthesis of N-hydroxyformamidine and its glutamyl pro-drug:
(i) Me2NCH(OMe2), reflux, 2 h, quantitative; (ii) NH2OHHCl, MeOH, 63%;
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comprise the parent NO-donor, a linker and a g-glutamyl
moiety. GABA-linked pro-drugs are not suitable substrates for
g-GT, but those linked by the aminobenzyl moiety proved to be
good substrates for the enzyme. The g-glutamyl group is cleaved
rapidly, with a slower decomposition of the aminobenzyl linker.
Improved design is now focussed on tuning the spacer to
encourage a more rapid release of the parent NHG drug.
The authors are grateful to the Wellcome Trust (Catalyst
Biomedica Development Award 063729/Z/01/Z) for financial support.
Thanks go to Prof. David O’Hagan (University of St Andrews) for
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